|
melanoma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
beta-catenin mutations have been found not only in melanoma and prostatic carcinoma but also in hepatocellular carcinomas in human, c-myc, H-ras genes transgenic mice and chemically-induced models.
|
10811985 |
2000 |
|
melanoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Beta-catenin is tyrosine phosphorylated in three melanoma cell lines and associates with both the ErbB2 receptor tyrosine kinase and the LAR receptor tyrosine phosphatase.
|
11245482 |
2001 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
β-catenin is a main driver in melanocyte development; although infrequently mutated in melanoma, its cellular localization and activity are frequently altered.
|
28191677 |
2017 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.
|
29664013 |
2018 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Beta-catenin has been identified as an oncogene in colon cancer and melanoma.
|
9377556 |
1997 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
A multifactorial analysis using Cox's regression model revealed that β-catenin, lymphoid enhancer-binding protein-1, heparanase-1, and the TNM stage were all independent factors in malignant melanoma (risk ratios were 7.294, 5.550, 5.622, and 4.794; p-values were 0.007, 0.018, 0.018, and 0.029, respectively).
|
25343173 |
2015 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A proportion of APC wild-type colon carcinomas and melanomas also contains constitutive nuclear Tcf-4/beta-catenin complexes as a result of dominant mutations in the N terminus of beta-catenin that render it insensitive to downregulation by APC, GSK3 beta, and Axin/Conductin.
|
10549354 |
2000 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
A significant fraction of primary human melanomas exhibit deregulation (via aberrant nuclear accumulation) of beta-catenin, leading us to examine its role in melanoma growth and survival.
|
12235125 |
2002 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although the role of WNT/β-catenin pathway in melanoma was early demonstrated, its contribution to the lack of the melanoma patient response to treatment was only recently recognized.
|
27351373 |
2016 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin.
|
15024079 |
2004 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Cell lines harboring mutant B-RAF or N-RAS were equally sensitive to LY2090314 as were those with acquired resistance to the BRAF inhibitor Vemurafenib. shRNA studies demonstrated that β-catenin stabilization is required for apoptosis following treatment with the GSK3 inhibitor since the sensitivity of melanoma cell lines to LY290314 could be overcome by β-catenin knockdown.
|
25915038 |
2015 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings support the notion that targeting the oncogenic β-catenin by lycorine is a new option to inhibit melanoma cell metastasis, providing a good drug candidate potential for development novel therapeutics against metastatic melanoma.
|
30565685 |
2019 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
LHGDN |
Compartmentalization in membrane rafts defines a pool of N-cadherin associated with catenins and not engaged in cell-cell junctions in melanoma cells.
|
17668445 |
2008 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
LHGDN |
Concomitantly, an increase in the nuclear level of beta-catenin occurred in melanoma cells, together with a sixfold increase in beta-catenin-dependent transcription.
|
15987741 |
2005 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Congruently, the transcriptional activity of β-catenin regulating expression of β-catenin target genes was not observed in several melanoma cell lines.
|
21584489 |
2011 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
LHGDN |
CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.
|
18563180 |
2008 |
|
melanoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma.
|
11351304 |
2001 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Directing this test to a single disease, 90 of 150 (60%) melanomas from sites throughout the body harbored a mutation tested, including 57, 23, 6, 3, and 2 mutations in BRAF, NRAS, GNAQ, KIT, and CTNNB1, respectively.
|
22536370 |
2012 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
E-cadherin, H-cadherin and β-catenin, prevalently found to be downregulated in melanoma, were diminished in MBrc.
|
21496114 |
2011 |
|
melanoma
|
0.500 |
AlteredExpression
|
disease |
LHGDN |
Expression of Wnt5a, MMP7, and beta-catenin was determined in 40 primary uveal melanomas by immunohistochemistry and correlated with patient prognosis.
|
17992121 |
2007 |
|
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Fifty percent of the hepatic tumors in these transgenic mice had activating somatic mutations within the beta-catenin gene similar to those found in colon cancers and melanomas.
|
9671767 |
1998 |
|
melanoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma.
|
10027390 |
1999 |
|
melanoma
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Genetic and epigenetic alterations of the APC gene in malignant melanoma.
|
15133491 |
2004 |
|
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here we report the isolation of a cDNA clone encoding beta-catenin, which was shown to be recognized by the tumor-infiltrating lymphocyte (TIL) 1290, a HLA-A24 restricted melanoma-specific CTL line from patient 888.
|
8642260 |
1996 |